L1 insertion variants in the MLH1 Gene

CGA-IGC 2026

Nov 02, 2026
Oncology
Presentation

Hannah Campbell, Michelle Mcsweeny, Marcy Richardson, Edward Anderson, Dylane Wineland, Marie Droual, Austin Eastmure, Michael J Hall

Background and Aim
Approximately 17% of the human genome is comprised of Long Interspersed Nuclear Element-1 retrotransposons (L1s). While most transposable elements are inactive, approximately 1/1000 spontaneous, disease-producing insertions in the human genome are caused by L1s. L1s have been described as a mechanism for hereditary cancer, including in Lynch Syndrome (LS). However, they are rarely reported on clinical testing as NGS panels are not designed to detect L1s optimally, and most L1s are intronic variants that are unlikely to impact cancer risk.

 

Methods
In collaboration with Ambry Genetics, we searched for reportable L1 insertions in LS-associated genes from a database of patients undergoing NGS-based cancer panel testing. Variants were analyzed for pathogenicity, association with LS cancers, and effect on splicing using hybrid-capture RNA-seq methodology.

 

Results
Three L1 variants were identified in the MLH1 gene. The MLH1 c.242_243insL1 and c.723_724insL1 variants are both within exons and are classified as likely pathogenic as they impact splicing via exon 3 and exon 9 skipping, respectively (Figure 1 and 2). The variants were identified in two families meeting NCCN criteria for LS germline testing. The MLH1 c.588+9_588+10insL1 variant is near-intronic, had no impact on RNA splicing, and is classified as likely benign (Figure 3). It was identified in seven unaffected probands with no significant family history of LS-cancers.

 

Conclusions
While L1 retrotransposons are common in the human genome, they are mostly present in non-coding regions. A study by a clinical genetic testing lab showed approximately 1/420 pathogenic variants identified in MLH1 were L1s. However, these elements are difficult to detect with routine NGS, and most are likely identified by chance. It is unknown how many clinically significant L1 variants may be missed using current standard genetic testing technologies, but more may be detected in the future as genetic testing technology advances.